>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息：
多发性骨髓瘤患者血清lncRNA PITPNA-AS1、lncRNA NORAD水平及其与患者预后的关系
作者：李红伟  司松环  杨靖  刘艳杰 
单位：郑州大学第一附属医院 血液科, 河南 郑州 450000
关键词：多发性骨髓瘤 长链非编码RNA PITPNA反义RNA1 长链非编码RNA NORAD 预后 
分类号：R733.3
出版年·卷·期（页码）：2024·43·第三期（450-455）
摘要：

目的: 分析多发性骨髓瘤(MM)患者血清长链非编码RNA(lncRNA) PITPNA反义RNA1(PITPNA-AS1)、lncRNA NORAD水平及其与患者预后的关系。方法:分别选择本院收治的96例MM患者和96例来本院健康查体的志愿者作为试验组和对照组,时间在2018年1月至2020年12月期间;采用实时荧光定量PCR(RT-qPCR)法检测两组血清中lncRNA PITPNA-AS1、lncRNA NORAD的相对表达量;采用Pearson相关分析分析血清lncRNA PITPNA-AS1与lncRNA NORAD水平的相关性;采用Kaplan-Meier生存分析分析血清lncRNA PITPNA-AS1、lncRNA NORAD水平与MM预后的关系;采用多元Cox回归分析MM患者预后的影响因素。结果:试验组血清lncRNA PITPNA-AS1、lncRNA NORAD水平显著高于对照组(P＜0.05)。Ⅲ期MM患者血清lncRNA PITPNA-AS1、lncRNA NORAD水平显著高于Ⅰ期和Ⅱ期,Ⅱ期显著高于Ⅰ期(P＜0.05)。MM患者血清lncRNA PITPNA-AS1与lncRNA NORAD水平呈正相关(r=0.636,P＜0.05)。lncRNA PITPNA-AS1和lncRNA NORAD高表达患者3年总生存率均低于低表达患者(χ2值分别为8.065、11.937,P值分别为0.005、0.001)。ISS分期较高、lncRNA PITPNA-AS1高水平、lncRNA NORAD高水平是MM患者预后的危险因素(P＜0.05)。结论:MM患者血清lncRNA PITPNA-AS1、lncRNA NORAD水平异常升高,且与患者预后关系密切。

Objective: To analyze the serum levels of long non-coding RNA(lncRNA) PITPNA antisense RNA1(PITPNA-AS1), lncRNA NORAD in patients with multiple myeloma(MM), and their relationship with prognosis. Methods: 96 patients with MM admitted to our hospital and 96 volunteers who came to our hospital for health checkups were selected as the experimental and control groups during January 2018 to December 2020, respectively; real-time fluorescence quantitative PCR(RT-qPCR) method was applied to detect the relative expression levels of serum lncRNA PITPNA-AS1 and lncRNA NORAD in two groups; Pearson correlation was applied to analyze the correlation between serum lncRNA PITPNA-AS1 and lncRNA NORAD levels; Kaplan-Meier survival was utilized to analyze the association between serum lncRNA PITPNA-AS1, lncRNA NORAD levels and MM prognosis; multiple Cox regression was utilized to analyze the factors influencing the prognosis of MM patients. Results: The serum levels of lncRNA PITPNA-AS1 and lncRNA NORAD in the experimental group were greatly higher than those in the control group(P＜0.05). The serum levels of lncRNA PITPNA-AS1 and lncRNA NORAD in patients with stage Ⅲ MM were greatly higher than those in stage Ⅰand Ⅱ, while the serum levels of lncRNA PITPNA-AS1 and lncRNA NORAD in patients with stage Ⅱ MM were greatly higher than those in stage Ⅰ(P＜0.05). There was a positive correlation between serum lncRNA PITPNA-AS1 and lncRNA NORAD levels in patients with MM(r=0.636, P＜0.05). Patients with high expression of both lncRNA PITPNA-AS1 and lncRNA NORAD had lower 3-year overall survival than patients with low expression(χ2:8.065, 11.937; P:0.005, 0.001). Higher ISS staging, high levels of lncRNA PITPNA-AS1, and high levels of lncRNA NORAD were prognostic risk factors for MM patients(P＜0.05). Conclusion: The serum levels of lncRNA PITPNA-AS1 and lncRNA NORAD are abnormally elevated in patients with MM, and are closely related to prognosis.
参考文献：

[1] BERNSTEIN Z S,KIM E B,RAJE N.Bone disease in multiple myeloma: biologic and clinical implications[J].Cells,2022,11(15):2308-2325.
[2] HUANG J,CHAN S C,LOK V,et al.The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends[J].Lancet Haematol,2022,9(9):e670-e677.
[3] BLADÉ J,BEKSAC M,CAERS J,et al.Extramedullary disease in multiple myeloma: a systematic literature review[J].Blood Cancer J,2022,12(3):45-54.
[4] WALLINGTON-BEDDOE C T,MYNOTT R L.Prognostic and predictive biomarker developments in multiple myeloma[J].J Hematol Oncol,2021,14(1):151-165.
[5] 陈生晓,甘艳,邝才花,等.LncRNA TUG1靶向调节miR-21/PTEN轴抑制糖尿病肾病大鼠肾纤维化的作用机制研究[J].东南大学学报(医学版),2023,42(2):218-227.
[6] LIU L,DAI A,ZHANG Z,et al.LncRNA PITPNA-AS1 promotes gastric cancer by increasing SOX4 expression via inhibition of miR-92a-3p[J].Aging(Albany NY),2021, 13(17):21191-21201.
[7] MAO W,WANG S,CHEN R,et al.lncRNA NORAD promotes lung cancer progression by competitively binding to miR-28-3p with E2F2[J].Open Med(Wars),2022,17(1):1538-1549.
[8] 胡文坛,刘俊文,刘红春,等.多发性骨髓瘤患者骨髓单个核细胞中Blimp-1 mRNA的检测及其临床意义[J].中国实验血液学杂志,2016,24(5):1443-1448.
[9] 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2017年修订)[J].中华内科杂志,2017, 56(11):866-870.
[10] DIAZ-DELCASTILLO M,CHANTRY A D,LAWSON M A,et al.Multiple myeloma-A painful disease of the bone marrow[J].Semin Cell Dev Biol,2021,112(1):49-58.
[11] GIRALT S,JOLLES S,KERRE T,et al.Recommendations for management of secondary antibody deficiency in multiple myeloma[J].Clin Lymphoma Myeloma Leuk,2023, 23(10):719-732.
[12] RODRIGUEZ-OTERO P,PAIVA B,SAN-MIGUEL J F.Roadmap to cure multiple myeloma[J]. Cancer Treat Rev,2021,100(1):e102284.
[13] GUO F,TANG C,HUANG B,et al.LncRNA H19 drives proliferation of cardiac fibroblasts and collagen production via suppression of the miR-29a-3p/miR-29b-3p-VEGFA/TGF-β axis[J].Mol Cells,2022,45(3):122-133.
[14] ABDI E,LATIFI-NAVID S,PANAHI A,et al.LncRNA polymorphisms and lung cancer risk[J]. Per Med,2023,20(6):511-522.
[15] 冯立新,翟传夫,谭清玉. LncRNA DLG1-AS1调控miR-203/ZEB2轴诱导甲状腺乳头状癌细胞恶性化生长和转移的机制研究[J].东南大学学报(医学版),2021,40(2):133-141.
[16] PENG B H,JI Y F, QIU X J.LncRNA PITPNA-AS1/miR-223-3p/PTN axis regulates malignant progression and stemness in lung squamous cell carcinoma[J].J Clin Lab Anal, 2022,36(7):e24506.
[17] WANG Q F,WANG Q L,CAO M B.LncRNA PITPNA-AS1 as a potential diagnostic marker and therapeutic target promotes hepatocellular carcinoma progression via modulating miR-448/ROCK1 axis[J].Front Med(Lausanne),2021,8(1):e668787.
[18] 饶琦,王丹丹,罗婷,等.lncRNA PITPNA-AS1靶向miR-367-3p调控多发性骨髓瘤细胞增殖、迁移和侵袭的分子机制[J].西部医学,2022,34(6):791-796,802.
[19] SOGHLI N,YOUSEFI T,ABOLGHASEMI M,et al.NORAD, a critical long non-coding RNA in human cancers[J].Life Sci,2021,264(1):e118665.
[20] LI Y,LV Y Y,WANG J Y,et al.LncRNA NORAD mediates the proliferation and apoptosis of diffuse large-b-cell lymphoma via regulation of miR-345-3p/TRAF6 axis[J].Arch Med Res, 2022,53(3):271-279.
[21] RAEI N,SAFARALIZADEH R,HOSSEINPOURFEIZI M,et al.Suppression of lncRNA NORAD may affect cell migration and apoptosis in gastric cancer cells[J].Mol Biol Rep, 2022,49(4):3289-3296.
[22] WANG K,CHEN Z,QIAO X,et al.LncRNA NORAD regulates the mechanism of the miR-532-3p/Nectin-4 axis in pancreatic cancer cell proliferation and angiogenesis[J].Toxicol Res(Camb),2023,12(3):425-432.
服务与反馈：
【文章下载】【发表评论】【查看评论】【加入收藏】
提示：您还未登录，请登录！点此登录
您是第 444811 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话：025-83272481 83272483
电子邮件： bjb@pub.seu.edu.cn

本系统由北京博渊星辰网络科技有限公司设计开发 技术支持电话：010-63361626

苏ICP备09058364